Kiniksa Pharmaceuticals International Plc (KNSA): Next-Year EPS Estimate 47.30%
As of 2026-08-25, Kiniksa Pharmaceuticals International Plc (KNSA) has a next-year EPS growth estimate of 47.30%. Featured in 4 EPS revision reports, most recently on 2026-07-31.
On 2026-08-13, analyst consensus for KNSA's next-year EPS growth shifted from 47.27% to 47.30% — a positive change of 0.03 percentage points. The revised estimate has been sustained across 11 subsequent trading sessions. Current-year growth is projected at 85.70%.
What's Driving This
Analysts raised KNSA’s next-year EPS growth estimate from 39.66% to 47.43% on July 29, a 7.77 percentage-point jump that served as the primary structural driver behind the stock’s rise. The upgrade followed Kiniksa’s strong Q2 2026 results and concurrent raise to full-year ARCALYST sales guidance, which provided a clear catalyst. The elevated estimate has persisted at 47.30%, indicating momentum has continued beyond the initial revision.
Generated 2026-08-25 from news as of 2026-08-25
Current Snapshot
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- EPS growth next year
- 47.30%
- EPS growth this year
- 85.70%
- EPS next quarter (est)
- $0.37
- Last price
- $80.20
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-08-25 | 47.30% | 85.70% | $0.37 | $80.20 |
| 2026-08-24 | 47.30% | 85.70% | $0.37 | $79.38 |
| 2026-08-23 | 47.30% | 85.70% | $0.37 | $79.03 |
| 2026-08-21 | 47.30% | 85.70% | $0.37 | $79.03 |
| 2026-08-20 | 47.30% | 85.70% | $0.37 | $78.47 |
| 2026-08-19 | 47.30% | 85.70% | $0.37 | $80.80 |
| 2026-08-18 | 47.30% | 85.70% | $0.37 | $79.49 |
| 2026-08-17 | 47.30% | 85.70% | $0.37 | $79.18 |
| 2026-08-16 | 47.30% | 85.70% | $0.37 | $76.75 |
| 2026-08-14 | 47.30% | 85.70% | $0.37 | $76.75 |
| 2026-08-13 | 47.30% | 85.70% | $0.37 | $77.83 |
| 2026-08-12 | 47.27% | 85.74% | $0.37 | $78.15 |
| 2026-08-11 | 47.30% | 85.70% | $0.37 | $77.80 |
| 2026-08-10 | 47.30% | 85.70% | $0.37 | $76.53 |
| 2026-08-09 | 47.30% | 85.70% | $0.37 | $76.06 |
| 2026-08-07 | 47.30% | 85.70% | $0.36 | $76.06 |
| 2026-08-06 | 47.30% | 85.70% | $0.36 | $76.51 |
| 2026-08-05 | 47.30% | 85.70% | $0.36 | $78.08 |
| 2026-08-04 | 47.30% | 85.70% | $0.36 | $75.99 |
| 2026-08-03 | 47.30% | 85.70% | $0.36 | $73.41 |
| 2026-08-02 | 47.43% | 85.80% | $0.36 | $74.34 |
| 2026-07-31 | 47.43% | 85.80% | $0.36 | $74.34 |
| 2026-07-30 | 47.43% | 85.80% | $0.36 | $78.20 |
| 2026-07-29 | 47.43% | 85.80% | $0.36 | $80.92 |
| 2026-07-28 | 39.66% | 80.79% | $0.30 | $79.44 |
| 2026-07-27 | 39.66% | 80.79% | $0.30 | $63.53 |
| 2026-07-26 | 39.66% | 80.79% | $0.30 | $62.84 |
| 2026-07-24 | 39.66% | 80.79% | $0.30 | $62.84 |
| 2026-07-23 | 39.66% | 80.79% | $0.30 | $63.05 |
| 2026-07-22 | 39.51% | 80.63% | $0.30 | $62.44 |
Reports Featuring KNSA
- 2026-07-31
NDLS +30.7% Leads EPS Revision Gainers; FFAI +28.1% Follows
- 2026-07-30
PMN Jumps 27.3% on EPS Revision and Alzheimer's Trial Data; KNSA, NDLS Follow
- 2026-07-29
KNSA Surges 28% on EPS Revision, Record Revenue; AMC, BZUN, CLF Also Climb
- 2026-07-28
CLF Surges 33.4% After EPS Revision; Steel Sector Leads
Recent News
- Kiniksa Pharmaceuticals, Ltd. Q2 2026 Earnings Call SummaryMoby
- Kiniksa Reports Strong Q2 Results, Raises 2026 ARCALYST Sales GuidanceInvestorsHub
- Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio ExecutionGlobeNewswire
- Kiniksa Pharmaceuticals to Report Second Quarter 2026 Financial Results on July 28, 2026GlobeNewswire
- Kiniksa Pharmaceuticals Reports First Quarter 2026 Financial Results and Recent Portfolio ExecutionGlobeNewswire
Screen Performance
Aggregate stats across all 2014 tickers our top-EPS-revision screen has flagged over the past 146 days.
- Median return since detection
- +3.1%
- % of tickers in the green
- 56%
- Median return on winners
- +19.9%
- Large revisions captured
- 1606
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Also Tracked by Our Screen
Frequently Asked Questions
What is Kiniksa Pharmaceuticals International Plc's next-year EPS growth estimate?▾
As of 2026-08-25, Kiniksa Pharmaceuticals International Plc (KNSA) has a next-year EPS growth estimate of 47.30%, based on analyst consensus.
When was the latest EPS estimate revision for KNSA?▾
The most recent revision occurred on 2026-08-13, when analysts adjusted the next-year EPS growth estimate from 47.27% to 47.30%.
What sector and industry does Kiniksa Pharmaceuticals International Plc belong to?▾
Kiniksa Pharmaceuticals International Plc operates in the Healthcare sector, specifically the Drug Manufacturers - Specialty & Generic industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. KNSA appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Kiniksa Pharmaceuticals International Plc (KNSA) appears here because it was detected by our daily top-EPS-revision-performer screen.